FDA Orphan Drug Director Sandra Retzky Reassigned Amid Inflation Reduction Act Policy Changes
核心洞察
Sandra Retzky (搜索), director of the FDA's Office of Orphan Products Development (搜索) since August 2021, has been reassigned within the agency during a critical period of rare disease policy changes.
The leadership change coincides with CMS finalizing new Inflation Reduction Act guidelines that expand orphan drug exemptions from Medicare price negotiations.
Retzky's departure follows a series of high-level FDA exits, including Nicole Verdun (搜索) from the Office of Therapeutic Products and Peter Marks (搜索) from the Center for Biologics Evaluation and Research.
Sandra Retzky (搜索), who has served as director of the FDA's Office of Orphan Products Development (搜索) since August 2021, has been reassigned within the agency amid significant policy changes affecting rare disease drug development. The departure was first reported by Endpoints News, with sources clarifying that Retzky had not been fired but transferred to another position within the FDA.
The leadership change occurs at a pivotal moment for orphan drug policy. The Centers for Medicare and Medicaid Services (搜索) recently finalized new Inflation Reduction Act guidelines that significantly expand exemptions for orphan drugs (搜索) from Medicare price negotiations. Under the revised rules, the countdown for qualifying for the negotiation program will start only after a drug is approved for a non-orphan indication, providing broader protections than the initial IRA framework.
Expanding Role of Orphan Drug Office
Retzky's office oversees the promotion and support of medical product development for rare diseases (搜索), including drugs, biologics, and devices. The department grants orphan drug status to products being developed for diseases affecting fewer than 200,000 patients in the U.S. and helps companies determine eligibility for various FDA designations, including orphan drug and rare pediatric disease awards.
The office also engages with the broader rare disease community, including patient groups, academia, and professional organizations, playing a crucial role in shaping policy that affects millions of Americans with rare conditions.
Policy Changes and Legislative Developments
The timing of Retzky's reassignment coincides with several major policy developments. CMS implemented amendments to the Orphan Drug Exclusion contained in the One Big Beautiful Bill Act, allowing drugs approved for multiple rare diseases (搜索) to remain excluded from negotiations provided their approved uses are only for rare conditions.
Additionally, the House Committee on Energy and Commerce recently cleared legislation that could restart the rare pediatric disease priority review voucher program. This program, first enacted in 2012 to incentivize investment in rare childhood diseases, was forced to wind down after Congress failed to renew it in September 2024.
Broader FDA Leadership Changes
Retzky's departure continues a pattern of high-level staffing changes at the Department of Health and Human Services (搜索) since Secretary Robert F. Kennedy Jr. took over the agency in February. The FDA has experienced significant turnover, with Nicole Verdun (搜索) being ousted from her role as director of the Office of Therapeutic Products in June, and Peter Marks (搜索) being forced out of the director post at the Center for Biologics Evaluation and Research in March.
Despite these changes, FDA staff have been spared from reductions in force affecting other HHS divisions, following discussions between FDA Commissioner Dr. Marty Makary (搜索) and White House budget officials.
Impact on Rare Disease Policy
The leadership transition comes as the FDA proposes changes to its rare disease policy framework. The agency has unveiled its Rare Disease Evidence Principles (RDEP) designed to accelerate the review and conditional approval of therapies for rare diseases (搜索), representing a significant shift in the regulatory approach to these conditions.
The reassignment also occurs as the FDA continues to implement new incentive programs, including the recently launched Commissioner's National Priority Review Vouchers, which awarded nine vouchers to sponsors developing products addressing major U.S. health priorities such as infertility (搜索), Type 1 diabetes (搜索), and nicotine addiction (搜索).